1. A FIRST‐IN‐HUMAN TRIAL OF THE NOVEL MULTI‐ACTION THERAPY TINOSTAMUSTINE (EDO‐S101) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) HODGKIN LYMPHOMA (HL). (12th June 2019) Authors: Pinto, A.; De Filippi, R.; Zinzani, P.; Driessen, C.; Tun, H.W.; Hilgier, K.; Remmy, D.; Mehrling, T.; O'Connor, O.A. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 326 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. THE DIAL STUDY (DUAL IMMUNOMODULATION IN AGGRESSIVE LYMPHOMA): RANDOMIZED PHASE 2 TRIAL OF VARLILUMAB PLUS NIVOLUMAB IN RELAPSED/REFRACTORY AGGRESSIVE B‐CELL LYMPHOMAS. (12th June 2019) Authors: Villasboas, J.C.; Reeder, C.B.; Tun, H.W.; Bartlett, N.L.; Sharon, E.; LaPlant, B.; Adjei, A.; Ansell, S.M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 70 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗